Published online before print July 31, 2003, doi: 10.1161/01.ATV.0000089329.09061.07
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2003 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Serum Chitotriosidase Activity Is Increased in Subjects With Atherosclerosis Disease
From Laboratorio de Investigación Molecular (M.A., A.C., C.G., F.C.), Servicio de Cardiología (J.M.C.), and Servicio de Medicina Interna (I.V., F.C.), Hospital Universitario Miguel Servet, Zaragoza; Departamento de Bioquímica y Biología Molecular y Celular (A.G., M.P.), Universidad de Zaragoza; Servicio de Neurología (I.J.), Hospital Clínico Universitario Lozano Blesa, Zaragoza; and Servicio de Bioquímica (J.P.), Hospital San Jorge, Huesca, Spain.
Correspondence to Marta Artieda, Laboratorio de Investigación Molecular, Hospital Universitario Miguel Servet, Isabel la Católica, 1-3, 50009 Zaragoza, Spain. E-mail martieda{at}hmservet.insalud.es
Objective— This study was undertaken to analyze the relation between serum activity of chitotriosidase enzyme, a protein synthesized exclusively by activated macrophages, and atherosclerotic lesion extent in subjects with atherothrombotic stroke (ATS) and in subjects with ischemic heart disease (IHD).
Methods and Results— We assayed the serum chitotriosidase activity and a common chitotriosidase gene polymorphism that causes deficiency in chitotriosidase activity in 3 Spanish populations, ATS (n=153), IHD (n=124), and control (n=148) subjects. Statistical differences were found in serum chitotriosidase activity between ATS (88.1±4.6 nmol/mL · h, P<0.0001) and IHD subjects (79.0±6.3, P=0.002) versus control group (70.9±5.2). These observed differences were not attributable to a distinct allelic or genotype distribution. The extension of the atherosclerotic lesion in carotids of ATS subjects was measured by duplex sonography. Chitotriosidase activities were 66.9±9.6, 88.7±8.3, and 107.7±11.8 for subjects with carotid stenosis 
30%, 31% to 60%, and >60%, respectively. Statistical differences were observed between subjects with major and intermediate stenosis grade compared with subjects with minor stenosis, P=0.005 and P=0.016, respectively.
Conclusions— Serum chitotriosidase activity is significantly increased in individuals suffering from atherosclerosis disease and is related to the severity of the atherosclerotic lesion, suggesting a possible role as atherosclerotic extent marker.
Key Words: chitotriosidase • macrophage • atherothrombotic stroke • ischemic heart disease • atherosclerosis
This article has been cited by other articles:
 |
|
 |
|
  F. Pappalardo, S. Musumeci, and S. Motta Modeling immune system control of atherogenesis Bioinformatics, August 1, 2008; 24(15): 1715 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Sotgiu, R Barone, G Arru, M L Fois, M Pugliatti, A Sanna, G Rosati, and S Musumeci Intrathecal chitotriosidase and the outcome of multiple sclerosis Multiple Sclerosis, September 1, 2006; 12(5): 551 - 557. [Abstract] [PDF]
|
|
|
|
 |
|
 L Malaguarnera, M Di Rosa, A M Zambito, N dell'Ombra, F Nicoletti, and M Malaguarnera Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease Gut, September 1, 2006; 55(9): 1313 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Anderson Candidate-based proteomics in the search for biomarkers of cardiovascular disease J. Physiol., February 15, 2005; 563(1): 23 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Fach, L.-A. Garulacan, J. Gao, Q. Xiao, S. M. Storm, Y. P. Dubaquie, S. A. Hefta, and G. J. Opiteck In Vitro Biomarker Discovery for Atherosclerosis by Proteomics Mol. Cell. Proteomics, December 1, 2004; 3(12): 1200 - 1210. [Abstract] [Full Text] [PDF]
|
|